Phillipov G, Mos E, Scinto S, Phillips P J
Endocrine Service, Queen Elizabeth Hospital, Woodville, South Australia.
Osteoporos Int. 1997;7(2):162-4. doi: 10.1007/BF01623693.
The effect of osteoporosis, as diagnosed by bone densitometry, on general practitioners' decisions to initiate hormone replacement therapy (HRT) was assessed. Data for the study were collected by questionnaire from 147 women (> 40 years), previously referred for measurement of bone mineral density (BMD) at the proximal forearm. Among the women, at the time of BMD measurement, current and ever use of HRT was 35% and 50% respectively, and 25.2% were osteoporotic on the basis of their BMD level. HRT was more likely to be initiated by women who were told that their BMD was low (ODR 3.4; 95% CI 1.2-9.7); 37% of all women with osteoporosis were using HRT compared with 78% who were taking calcium supplements. Potential reasons for the low HRT prescription may include the nature of the BMD report, patient aversion to HRT and doctors' concern with the long-term side-effects of HRT.
评估了通过骨密度测定诊断的骨质疏松症对全科医生启动激素替代疗法(HRT)决策的影响。该研究的数据通过问卷调查收集自147名年龄大于40岁、此前被转诊至前臂近端进行骨矿物质密度(BMD)测量的女性。在这些女性中,在进行BMD测量时,当前使用HRT和曾经使用HRT的比例分别为35%和50%,并且根据她们的BMD水平,25.2%患有骨质疏松症。被告知其BMD较低的女性更有可能启动HRT(优势比3.4;95%置信区间1.2 - 9.7);所有患有骨质疏松症的女性中,37%正在使用HRT,而服用钙补充剂的比例为78%。HRT处方率低的潜在原因可能包括BMD报告的性质、患者对HRT的厌恶以及医生对HRT长期副作用的担忧。